




RealRate

PHARMACEUTICAL 2022

VYNE Therapeutics Inc.
Rank 427 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

VYNE Therapeutics Inc. Rank 427 of 475



The relative strengths and weaknesses of VYNE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 45% points. The greatest weakness of VYNE Therapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 310% points.

The company's Economic Capital Ratio, given in the ranking table, is -572%, being 295% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	63,186
Cost of Goods Sold	3,348
Intangible Assets	0
Liabilities, Current	18,410
Liabilities, Non-Current	0
Other Assets	3,506
Other Compr. Net Income	0
Other Expenses	5,162
Other Liabilities	0
Other Net Income	-135
Property and Equipment	354
Research and Development	24,958
Revenues	14,755
Selling, General and Administrative Expense	54,481

Output Variable	Value in 1000 USD
Assets	67,046
Liabilities	18,410
Expenses	87,949
Stockholders Equity	48,636
Net Income	-73,329
Comprehensive Net Income	-73,329
Economic Capital Ratio	-572%

